
CYNBIOSE
Supporting biomedical research with translational preclinical models.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
* | €1.9m | Seed | |
Total Funding | 000k |
EUR | 2015 | 2016 | 2017 | 2018 | 2019 |
---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (25 %) | - | - | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (22 %) | - | - | - | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Cynbiose specializes in providing preclinical research services to stakeholders in the life sciences industry, including large and mid-sized pharmaceutical companies, biotech firms, startups, and academic research teams. The company operates in the niche market of non-human primate (NHP) models, which are crucial for the development of innovative therapies. Cynbiose's business model revolves around offering expertise, consultancy, and services that are clinically relevant, flexible, cost-effective, and adhere to the highest quality standards. The company generates revenue through service contracts with its diverse client base. Cynbiose is committed to animal welfare, as evidenced by its AAALAC accreditation, and employs positive reinforcement techniques to reduce animal stress. Strategic partnerships further enhance its service offerings and market reach.
Keywords: preclinical research, non-human primate models, innovative therapies, life sciences, pharmaceutical, biotech, academic research, consultancy, animal welfare, strategic partnerships.